Does the media favor MDGL or ZLAB?

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat Madrigal Pharmaceuticals' score of 0.34 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMRN or ZLAB?

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for BioMarin Pharmaceutical and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat BioMarin Pharmaceutical's score of 0.35 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, IBRX or ZLAB?

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 91.68 -$351.40M -$0.97 N/A Zai Lab $460.16M 5.71 -$175.54M -$1.71 N/A

Is IBRX or ZLAB more profitable?

Zai Lab has a net margin of -41.86% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer IBRX or ZLAB?

In the previous week, ImmunityBio had 8 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for ImmunityBio and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat ImmunityBio's score of 0.43 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ZLAB or PCVX?

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 5.71 -$175.54M -$1.71 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is ZLAB or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Vaxcyte N/A -37.56% -33.62%

Does the media prefer ZLAB or PCVX?

In the previous week, Vaxcyte had 16 more articles in the media than Zai Lab. MarketBeat recorded 19 mentions for Vaxcyte and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat Vaxcyte's score of 0.36 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 4 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, KRYS or ZLAB?

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 24.43 $204.83M $7.98 40.25 Zai Lab $460.16M 5.71 -$175.54M -$1.71 N/A

Is KRYS or ZLAB more profitable?

Krystal Biotech has a net margin of 54.82% compared to Zai Lab's net margin of -41.86%. Krystal Biotech's return on equity of 19.34% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer KRYS or ZLAB?

In the previous week, Krystal Biotech had 7 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Krystal Biotech and 3 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 0.70 beat Zai Lab's score of 0.58 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zai Lab (ZLAB) Competitors

$22.67 -0.43 (-1.88%)

As of 10:59 AM Eastern

Compare

ZLAB vs. MDGL, BMRN, IBRX, PCVX, and KRYS

Should you buy Zai Lab stock or one of its competitors? Zai Lab's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), BioMarin Pharmaceutical (BMRN), ImmunityBio (IBRX), Vaxcyte (PCVX), and Krystal Biotech (KRYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zai Lab compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Zai Lab	-41.86%	-27.43%	-16.72%

Madrigal Pharmaceuticals has a beta of -1.04, meaning that its stock price is 204% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Zai Lab has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	10.90	-$288.28M	-$12.89	N/A
Zai Lab	$460.16M	5.71	-$175.54M	-$1.71	N/A

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat Madrigal Pharmaceuticals' score of 0.34 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Madrigal Pharmaceuticals presently has a consensus price target of $710.20, suggesting a potential upside of 57.08%. Zai Lab has a consensus price target of $37.25, suggesting a potential upside of 61.26%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Madrigal Pharmaceuticals and Zai Lab tied by winning 8 of the 16 factors compared between the two stocks.

How does Zai Lab compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for BioMarin Pharmaceutical and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat BioMarin Pharmaceutical's score of 0.35 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.27	$348.90M	$0.37	146.97
Zai Lab	$460.16M	5.71	-$175.54M	-$1.71	N/A

BioMarin Pharmaceutical currently has a consensus target price of $88.74, suggesting a potential upside of 63.18%. Zai Lab has a consensus target price of $37.25, suggesting a potential upside of 61.26%. Given BioMarin Pharmaceutical's higher possible upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.71
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Zai Lab's net margin of -41.86%. BioMarin Pharmaceutical's return on equity of 5.32% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Zai Lab	-41.86%	-27.43%	-16.72%

Summary

BioMarin Pharmaceutical beats Zai Lab on 11 of the 16 factors compared between the two stocks.

How does Zai Lab compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

In the previous week, ImmunityBio had 8 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for ImmunityBio and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat ImmunityBio's score of 0.43 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a net margin of -41.86% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Zai Lab	-41.86%	-27.43%	-16.72%

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 44.90%. Zai Lab has a consensus price target of $37.25, indicating a potential upside of 61.26%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	91.68	-$351.40M	-$0.97	N/A
Zai Lab	$460.16M	5.71	-$175.54M	-$1.71	N/A

Summary

Zai Lab beats ImmunityBio on 8 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Vaxcyte?

Zai Lab (NASDAQ:ZLAB) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Vaxcyte	N/A	-37.56%	-33.62%

Zai Lab presently has a consensus target price of $37.25, suggesting a potential upside of 61.26%. Vaxcyte has a consensus target price of $110.50, suggesting a potential upside of 65.42%. Given Vaxcyte's higher probable upside, analysts clearly believe Vaxcyte is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	5.71	-$175.54M	-$1.71	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Zai Lab has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

In the previous week, Vaxcyte had 16 more articles in the media than Zai Lab. MarketBeat recorded 19 mentions for Vaxcyte and 3 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.58 beat Vaxcyte's score of 0.36 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zai Lab beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Krystal Biotech currently has a consensus target price of $377.20, indicating a potential upside of 17.45%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 61.26%. Given Zai Lab's higher probable upside, analysts clearly believe Zai Lab is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Krystal Biotech had 7 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Krystal Biotech and 3 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 0.70 beat Zai Lab's score of 0.58 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.43	$204.83M	$7.98	40.25
Zai Lab	$460.16M	5.71	-$175.54M	-$1.71	N/A

Krystal Biotech has a net margin of 54.82% compared to Zai Lab's net margin of -41.86%. Krystal Biotech's return on equity of 19.34% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Zai Lab	-41.86%	-27.43%	-16.72%

Summary

Krystal Biotech beats Zai Lab on 13 of the 16 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.57B	$3.88B	$7.26B	$13.10B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-13.21	13.21	275.54	25.58
Price / Sales	5.58	1,131.68	557.67	80.26
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	3.53	17.16	10.81	6.02
Net Income	-$175.54M	-$22.65M	$3.49B	$380.34M
7 Day Performance	-10.90%	-4.64%	-3.00%	-3.19%
1 Month Performance	-8.26%	-12.66%	-7.48%	-6.07%
1 Year Performance	-23.30%	8.08%	3.18%	-3.77%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.8088 of 5 stars	$22.67 -1.9%	$37.25 +64.3%	-26.0%	$2.57B	$460.16M	N/A	1,784	News Coverage Gap Down
MDGL Madrigal Pharmaceuticals	2.9507 of 5 stars	$496.45 +0.6%	$710.20 +43.1%	+5.7%	$11.40B	$958.40M	N/A	915	Analyst Forecast
BMRN BioMarin Pharmaceutical	4.245 of 5 stars	$56.22 -2.3%	$89.17 +58.6%	+3.7%	$11.14B	$3.22B	151.95	3,221	Analyst Upgrade
IBRX ImmunityBio	2.9801 of 5 stars	$9.69 -6.6%	$14.20 +46.5%	+295.2%	$11.00B	$113.29M	N/A	691
PCVX Vaxcyte	2.8185 of 5 stars	$66.70 -9.6%	$108.60 +62.8%	+52.5%	$10.98B	N/A	N/A	507	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors

ZLAB vs. MDGL, BMRN, IBRX, PCVX, and KRYS

How does Zai Lab compare to Madrigal Pharmaceuticals?

Summary

How does Zai Lab compare to BioMarin Pharmaceutical?

Summary

How does Zai Lab compare to ImmunityBio?

Summary

How does Zai Lab compare to Vaxcyte?

Summary

How does Zai Lab compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zai Lab (ZLAB) Competitors

ZLAB vs. MDGL, BMRN, IBRX, PCVX, and KRYS

How does Zai Lab compare to Madrigal Pharmaceuticals?

Is MDGL or ZLAB more profitable?

Which has more volatility & risk, MDGL or ZLAB?

Which has preferable earnings & valuation, MDGL or ZLAB?

Does the media favor MDGL or ZLAB?

Do institutionals and insiders hold more shares of MDGL or ZLAB?

Do analysts recommend MDGL or ZLAB?

Summary

How does Zai Lab compare to BioMarin Pharmaceutical?

Does the media favor BMRN or ZLAB?

Which has better earnings and valuation, BMRN or ZLAB?

Do analysts recommend BMRN or ZLAB?

Do insiders and institutionals have more ownership in BMRN or ZLAB?

Which has more volatility and risk, BMRN or ZLAB?

Is BMRN or ZLAB more profitable?

Summary

How does Zai Lab compare to ImmunityBio?

Which has more risk & volatility, IBRX or ZLAB?

Does the media prefer IBRX or ZLAB?

Is IBRX or ZLAB more profitable?

Do institutionals & insiders believe in IBRX or ZLAB?

Do analysts prefer IBRX or ZLAB?

Which has stronger valuation & earnings, IBRX or ZLAB?

Summary

How does Zai Lab compare to Vaxcyte?

Do institutionals and insiders have more ownership in ZLAB or PCVX?

Is ZLAB or PCVX more profitable?

Do analysts recommend ZLAB or PCVX?

Which has better earnings and valuation, ZLAB or PCVX?

Which has more risk & volatility, ZLAB or PCVX?

Does the media prefer ZLAB or PCVX?

Summary

How does Zai Lab compare to Krystal Biotech?

Which has more volatility & risk, KRYS or ZLAB?

Do analysts prefer KRYS or ZLAB?

Do insiders & institutionals have more ownership in KRYS or ZLAB?

Does the media prefer KRYS or ZLAB?

Which has better earnings & valuation, KRYS or ZLAB?

Is KRYS or ZLAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools